Patent ID: 8053445

Claim:
A method of enhancing the expression of apoAI, which comprises administrating a therapeutically effective amount of a compound of formula (I): in which Ar 1 and Ar 2 are independently a phenyl that may be optionally substituted, or a naphthyl that may be optionally substituted; —X— is a group of formula (α): wherein the broken line is the presence or absence of a bond; -Q= is a group of when the broken line is the presence of a bond; -Q- is —CY 2 Y 3 — or —NY 4 — when the broken line is the absence of a bond; Y 2 and Y 3 are independently a hydrogen, a halogen, a lower alkyl that may be optionally substituted, a carboxy, a lower alkoxycarbonyl that may be optionally substituted, a cyano, a monocyclic carbocyclic group that may be optionally substituted, or a monocyclic heterocyclic group that may be optionally substituted, Y 4 is a hydrogen or a lower alkyl; Z 2 is a linker group comprising 1 to 2 atoms that combines with the constituent atoms of the ring Ar 1 that are bonded to Z 2 via the two atoms to form a condensed ring; provided that, when both Ar 1 and Ar 2 are a phenyl that may be optionally substituted, then Y 2 is not a phenyl that may be optionally substituted; wherein the optional substituent of the phenyl and the naphthyl from the definition of Ar 1 and Ar 2 , and the monocyclic carbocyclic group and the monocyclic heterocyclic group from the definition of Y 2 and Y 3 is selected from the group consisting of a halogen; a hydroxy; a lower alkyl optionally substituted by a halogen, a hydroxy, or a lower alkoxy; a lower alkoxy optionally substituted by a halogen, a hydroxy, a carboxy, or a lower alkoxycarbonyl; a lower alkenyl optionally substituted by a halogen or a hydroxy; a lower alkenyloxy optionally substituted by a halogen or a hydroxy; a lower alkylthio; a non-aromatic carbocyclic group optionally substituted by a halogen, a hydroxy, or a lower alkyl; an acyl; an acyloxy; a carboxy; a lower alkoxycarbonyl; a lower alkenyloxycarbonyl; an amino optionally substituted by a lower alkyl or an acyl; a hydrazino; a nitro; a cyano; a phenyl or naphthyl optionally substituted by a halogen, a hydroxy, a lower alkyl or a lower alkoxy; a heterocyclic group; a phenoxy optionally substituted by a halogen, a hydroxy, or a lower alkyl; a monocyclic aromatic heterocyclic oxy; an oxo; and an alkylenedioxy optionally substituted by a lower alkyl, a lower alkoxy or a phenyl group; and wherein the optional substituent of the lower alkyl and lower alkoxycarbonyl in the definition of Y 2 and Y 3 is selected from the group consisting of a halogen, a hydroxy, a lower alkoxy, a monocyclic group, a bicyclic carbocyclic group, an acyl, an acyloxy, a carboxy, a lower alkoxycarbonyl, an amino, a lower alkylamino, a nitro, a monocyclic group and a bicyclic heterocyclic group; or a pharmaceutically acceptable salt thereof to a patient expected to enhance the expression of apoAI.